ClinicalTrials.gg
CompletedNCT02920008Updated Aug 28, 2024Results posted

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

A Phase 3 interventional study of guadecitabine and Treatment Choice (TC) in Acute Myeloid Leukemia, sponsored by Astex Pharmaceuticals, Inc.. Completed at 95 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. — 4 open to participants now, 6 under way, 2 of them phase 3. Leukemia, Myeloid, Acute · Otsuka Holdings Co., Ltd..

Enrollment
4th of 20
302 · median 42
Started
2017
the only one that year
Phase 3
4 of 20
none open now
Registered
8th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 8th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC. TC options include the 8 high or low intensity, locally available regimens below; or Best supportive Care (BSC) alone:

  • High intensity (intermediate or high dose cytarabine [HiDAC]; mitoxantrone, etoposide, and cytarabine [MEC]; or fludarabine, cytarabine, granulocyte colony stimulating factor [G-CSF], +/- idarubicin [FLAG/FLAG-Ida]).
  • Low intensity (low dose cytarabine [LDAC], decitabine, or azacitidine).
  • BSC.
Read the detailed description

This Phase 3, randomized, open-label, parallel-group multicenter study of the efficacy and safety of guadecitabine in adults with previously treated acute myeloid leukemia (AML) will be conducted in approximately 20 countries. There will be a 14-day screening period, a treatment period, a safety follow-up visit, and a long-term follow-up period. The study is expected to last approximately 2 years. Duration of individual participant participation will vary, and participants may continue to receive treatment for as long as they continue to benefit.

Approximately 404 participants from approximately 100 study centers will be randomly assigned to either guadecitabine or treatment choice (TC) in a 1:1 ratio (approximately 202 participants per group). TC is as follows:

  • High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).
  • Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.
  • Best Supportive Care (BSC).

Guadecitabine will be given subcutaneous (SC) at a dose of 60 microgram per meter square (mg/m\^2) in 28-day cycles. In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. Cycle 2 will be either the 5-day regimen (Days 1-5) or 10-day regimen (Days 1-5 and 8-12) based on assessment of disease response and hematologic recovery at the end of Cycle 1. In subsequent cycles, guadecitabine treatment will be for 5 days only (Days 1-5).

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML, acute myeloid leukemia, guadecitabine, SGI-110, Phase 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult participants ≥18 years of age who are able to understand study procedures, comply with them, and provide written before any study-specific procedure.
  2. History of or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts ≥20%).
  3. Performance status (; ECOG) of 0-2.
  4. Participants with AML previously treated with initial induction therapy using a standard intensive chemotherapy regimen, including cytarabine and an anthracycline, and who are to initial induction (primary refractory) or in relapse after such initial induction with or without prior HCT.
  5. Participants must have either PB or BM blasts ≥5% at time of randomization.
  6. or ≥30 mL/min as estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas, such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology Collaboration).
  7. Women of must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment of guadecitabine, decitabine, or azacitidine and for at least 3 months after completing treatment and (b) while receiving treatment with high-intensity TC or LDAC and for at least 6 months after completing treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
  2. Participants who are in first relapse after initial induction, if they had a response duration of >12 months from date when first response first documented or if they are good candidates for HCT.
  3. BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  4. Second currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
  5. Grade 3 or higher (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day.
  6. Prior treatment with guadecitabine for any indication, or more than 2 cycles of prior decitabine or azacitidine.
  7. to decitabine, guadecitabine, or any of their .
  8. Treated with any therapy within 2 weeks of the first dose of study treatment.
  9. Total serum >2.5 × (ULN; except for participants with Gilbert's Syndrome for whom direct bilirubin is \<2.5 × ULN), or liver cirrhosis, or chronic liver disease Class B or C.
  10. Known active (HIV), virus (HBV), or virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
  11. Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol.
  12. congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AML-associated pulmonary disease requiring >2 liters per minute (LPM) oxygen, or any other condition that puts the participant at an imminent risk of death.
  13. Participants with high PB blasts >50% AND poor PS of 2.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    guadecitabine

    Guadecitabine will be given SC at a dose of 60 mg/m\^2 in 28-day cycles (delayed as necessary to allow blood count recovery).

    Drug: guadecitabine

  • Active comparator
    Treatment Choice (TC)

    1. High intensity 2. Low intensity 3. Best supportive care (BSC).

    Drug: Treatment Choice (TC)

Interventions

  • In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m\^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.

    Also known as: SGI-110

  • DrugTreatment Choice (TC)

    * High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida). * Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine. * Best Supportive Care (BSC).

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as number of days from day of randomization to date of death, regardless of cause.

    Time frame: From the date of randomization until the date of death, or approximately 34 months

Secondary outcomes

  1. Event-Free Survival

    Event-free survival is defined as number of days from randomization to earliest date of treatment discontinuation (for reasons other than initiation of hematopoietic cell transplant \[HCT\]), start of alternative anti-leukemia therapy (except HCT), or death.

    Time frame: From the date of randomization until the date of death, or approximately 38 months

  2. Long-Term Survival

    Survival rate at 1 year after randomization; participants were also followed to estimate 2-year survival rate.

    Time frame: Up to approximately 38 months

  3. Number of Days Alive and Out of the Hospital (NDAOH)

    Number of days participants alive and out of hospital during first 6 months of the study.

    Time frame: 6 months

  4. Transfusion Independence Rate

    Number of participants without red blood cells (RBC) or platelet transfusion for any 8-week period after treatment divided by total number of participants in efficacy analysis.

    Time frame: Baseline up to approximately 38 months

  5. Complete Response Rate

    The Complete response (CR) rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as the number of participants with a best response of CR divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.

    Time frame: Baseline to end of treatment, or approximately 38 months

  6. Combined Complete Response and Complete Response With Partial Hematologic Recovery Rate

    The combined CR and CR with partial hematologic recovery rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as number of participants with CR and CR with partial hematologic recovery divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.

    Time frame: Baseline to end of treatment, or approximately 38 months

  7. Composite Complete Response Rate

    Composite complete response rate based on modified IWG 2003 AML Response Criteria defined as number of participants with best response of CR, CR with incomplete platelet recovery (CRp), or CR with incomplete blood count recovery (CRi) divided by total number of participants in efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is ANC ≥1000/μL, platelets ≥100,000/μL, independence from RBC and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. CRp is defined as ANC ≥1000/μL, Platelets \<100,000/μL, independence from RBC transfusions over the past week, no leukemic blasts and bone marrow should contain less than 5% blast cells. CRi is defined as ANC \<1000/μL, no leukemic blasts and bone marrow should contain less than 5% blast cells.

    Time frame: Baseline to end of treatment, or approximately 38 months

  8. Hematopoietic Cell Transplant (HCT) Rate

    Number of participants who received HCT after randomization divided by total number of participants in efficacy analysis.

    Time frame: Baseline to long term follow-up or approximately 38 months

  9. Duration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh)

    The time from first CR or CRh to time of relapse (the date of the earliest of the following 3 events): 1. relapse (defined as the earliest time point whereby BM assessment or PB assessment by the investigator indicate relapse/disease progression due to confirmed reappearance of leukemic blasts in PB or ≥5% leukemic blasts in BM, or clinical progression determined by the investigator), 2. start of alternative therapy (except HCT) or 3. death.

    Time frame: Baseline to end of treatment, or approximately 38 months

  10. Change From Baseline in EuroQoL-5 Dimension 5 Level (EQ-5D-5L) Index Scores

    Index score is calculated based on 5-level version of the EQ-5D descriptive system using the value set for England. The range of index score is from -0.281 (for the worst health state, score of 5 for all categories) to 1 (for the best health state, score of 1 for all categories).

    Time frame: Baseline to 6 months

  11. Change in EQ-5D-5L Visual Analogue Scale (VAS) Score

    VAS score is obtained using vertical 20-cm visual analogue scale with the top value of 100 labelled as 'the best health you can imagine' and the bottom value of 0 labelled as 'the worst health you can imagine'.

    Time frame: Baseline to 6 months

  12. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.

    Time frame: From first dose until 30 days after the last dose of study drug, or approximately 38 months

  13. All-Cause Mortality

    All-cause mortality in the first 30 days and first 60 days after the start of treatment divided by the total number of participants receiving at least one dose of study treatment.

    Time frame: From the first dose until 60 days after the first dose of study drug

07

Results

Posted May 25, 2023

Participant flow

A total of 358 participants were assessed for study inclusion. Of these 56 failed screening assessments. A total of 302 participants were randomized (148 guadecitabine, 154 treatment choice \[TC\]). Of the randomized participants, 10 did not receive study drug (3 guadecitabine, 7 TC).

Participant flow — Overall Study
MilestoneGuadecitabineTreatment Choice (TC)
Started148154
Safety analysis set145147
Completed2820
Not completed120134
Withdrew: Death117127
Withdrew: Withdrawal by subject36
Withdrew: Lost to follow-up01

Outcome measures

PrimaryOverall Survival

Overall survival is defined as number of days from day of randomization to date of death, regardless of cause.

Time frame:
From the date of randomization until the date of death, or approximately 34 months
Reported as:
Median · days
Overall Survival
daysGuadecitabineTreatment Choice (TC)
Overall Survival191.0 (141.0 to 253.0)163.0 (131.0 to 213.0)
Statistical analysis
  • Guadecitabine vs Treatment Choice (TC) · Stratified log-rank · p = = 0.3287
SecondaryEvent-Free Survival

Event-free survival is defined as number of days from randomization to earliest date of treatment discontinuation (for reasons other than initiation of hematopoietic cell transplant \[HCT\]), start of alternative anti-leukemia therapy (except HCT), or death.

Time frame:
From the date of randomization until the date of death, or approximately 38 months
Reported as:
Median · days
Event-Free Survival
daysGuadecitabineTreatment Choice (TC)
Event-Free Survival90.0 (73.0 to 105.0)71.5 (53.0 to 78.0)
SecondaryLong-Term Survival

Survival rate at 1 year after randomization; participants were also followed to estimate 2-year survival rate.

Time frame:
Up to approximately 38 months
Reported as:
Number · proportion
Long-Term Survival
proportionGuadecitabineTreatment Choice (TC)
12-month survival rate0.32 (0.25 to 0.40)0.26 (0.20 to 0.34)
24-month survival rate0.19 (0.12 to 0.26)0.10 (0.05 to 0.17)
SecondaryNumber of Days Alive and Out of the Hospital (NDAOH)

Number of days participants alive and out of hospital during first 6 months of the study.

Time frame:
6 months
Reported as:
Geometric least squares mean · days
Number of Days Alive and Out of the Hospital (NDAOH)
daysGuadecitabineTreatment Choice (TC)
Number of Days Alive and Out of the Hospital (NDAOH)73.2 (53.2 to 93.2)73.9 (53.8 to 94.1)
SecondaryTransfusion Independence Rate

Number of participants without red blood cells (RBC) or platelet transfusion for any 8-week period after treatment divided by total number of participants in efficacy analysis.

Time frame:
Baseline up to approximately 38 months
Reported as:
Number · percentage of participants
Transfusion Independence Rate
percentage of participantsGuadecitabineTreatment Choice (TC)
Overall transfusion independence20.313.0
Platelet transfusion independence23.621.4
RBC transfusion independence21.614.3
SecondaryComplete Response Rate

The Complete response (CR) rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as the number of participants with a best response of CR divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.

Time frame:
Baseline to end of treatment, or approximately 38 months
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsGuadecitabineTreatment Choice (TC)
Complete Response Rate12.87.1
SecondaryCombined Complete Response and Complete Response With Partial Hematologic Recovery Rate

The combined CR and CR with partial hematologic recovery rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as number of participants with CR and CR with partial hematologic recovery divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) ≥1000/μL, platelets ≥100,000/μL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells.

Time frame:
Baseline to end of treatment, or approximately 38 months
Reported as:
Number · percentage of participants
Combined Complete Response and Complete Response With Partial Hematologic Recovery Rate
percentage of participantsGuadecitabineTreatment Choice (TC)
Combined Complete Response and Complete Response With Partial Hematologic Recovery Rate16.97.8
SecondaryComposite Complete Response Rate

Composite complete response rate based on modified IWG 2003 AML Response Criteria defined as number of participants with best response of CR, CR with incomplete platelet recovery (CRp), or CR with incomplete blood count recovery (CRi) divided by total number of participants in efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is ANC ≥1000/μL, platelets ≥100,000/μL, independence from RBC and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. CRp is defined as ANC ≥1000/μL, Platelets \<100,000/μL, independence from RBC transfusions over the past week, no leukemic blasts and bone marrow should contain less than 5% blast cells. CRi is defined as ANC \<1000/μL, no leukemic blasts and bone marrow should contain less than 5% blast cells.

Time frame:
Baseline to end of treatment, or approximately 38 months
Reported as:
Number · percentage of participants
Composite Complete Response Rate
percentage of participantsGuadecitabineTreatment Choice (TC)
Composite Complete Response Rate27.014.3
SecondaryHematopoietic Cell Transplant (HCT) Rate

Number of participants who received HCT after randomization divided by total number of participants in efficacy analysis.

Time frame:
Baseline to long term follow-up or approximately 38 months
Reported as:
Number · percentage of participants
Hematopoietic Cell Transplant (HCT) Rate
percentage of participantsGuadecitabineTreatment Choice (TC)
Hematopoietic Cell Transplant (HCT) Rate17.616.2
SecondaryDuration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh)

The time from first CR or CRh to time of relapse (the date of the earliest of the following 3 events): 1. relapse (defined as the earliest time point whereby BM assessment or PB assessment by the investigator indicate relapse/disease progression due to confirmed reappearance of leukemic blasts in PB or ≥5% leukemic blasts in BM, or clinical progression determined by the investigator), 2. start of alternative therapy (except HCT) or 3. death.

Time frame:
Baseline to end of treatment, or approximately 38 months
Reported as:
Median · days
Duration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh)
daysGuadecitabineTreatment Choice (TC)
Duration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh)124 (73.0 to 315.0)63 (8.0 to 71.0)
SecondaryChange From Baseline in EuroQoL-5 Dimension 5 Level (EQ-5D-5L) Index Scores

Index score is calculated based on 5-level version of the EQ-5D descriptive system using the value set for England. The range of index score is from -0.281 (for the worst health state, score of 5 for all categories) to 1 (for the best health state, score of 1 for all categories).

Time frame:
Baseline to 6 months
Reported as:
Geometric least squares mean · score on a scale
Change From Baseline in EuroQoL-5 Dimension 5 Level (EQ-5D-5L) Index Scores
score on a scaleGuadecitabineTreatment Choice (TC)
Cycle 2 Day 1-0.027 (-0.061 to 0.007)-0.034 (-0.068 to 0.001)
Cycle 3 Day 1-0.026 (-0.063 to 0.011)-0.028 (-0.066 to 0.010)
Cycle 4 Day 1-0.008 (-0.050 to 0.034)-0.061 (-0.108 to -0.015)
Cycle 5 Day 1-0.022 (-0.072 to 0.027)-0.072 (-0.126 to -0.019)
Cycle 6 Day 1-0.027 (-0.071 to 0.017)-0.070 (-0.188 to -0.022)
Cycle 7 Day 1-0.020 (-0.071 to 0.030)-0.022 (-0.076 to 0.033)
SecondaryChange in EQ-5D-5L Visual Analogue Scale (VAS) Score

VAS score is obtained using vertical 20-cm visual analogue scale with the top value of 100 labelled as 'the best health you can imagine' and the bottom value of 0 labelled as 'the worst health you can imagine'.

Time frame:
Baseline to 6 months
Reported as:
Geometric least squares mean · score on a scale
Change in EQ-5D-5L Visual Analogue Scale (VAS) Score
score on a scaleGuadecitabineTreatment Choice (TC)
Cycle 2 Day 1-2.80 (-6.26 to 0.65)-1.86 (-5.40 to 1.67)
Cycle 3 Day 1-0.61 (-4.08 to 2.87)-1.47 (-5.02 to 2.08)
Cycle 4 Day 11.13 (-2.24 to 4.51)-2.37 (-6.04 to 1.29)
Cycle 5 Day 11.28 (-2.88 to 5.44)-2.30 (-6.83 to 2.22)
Cycle 6 Day 10.67 (-3.51 to 4.85)-1.42 (-6.04 to 3.21)
Cycle 7 Day 1-0.44 (-5.66 to 4.78)-0.77 (-6.46 to 4.93)
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality.

Time frame:
From first dose until 30 days after the last dose of study drug, or approximately 38 months
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsGuadecitabineTreatment Choice (TC)
Percentage of Participants With Adverse Events (AEs)96.697.3
SecondaryAll-Cause Mortality

All-cause mortality in the first 30 days and first 60 days after the start of treatment divided by the total number of participants receiving at least one dose of study treatment.

Time frame:
From the first dose until 60 days after the first dose of study drug
Reported as:
Number · percentage of participants
All-Cause Mortality
percentage of participantsGuadecitabineTreatment Choice (TC)
Within 30 days11.79.5
Within 60 days24.820.4

Adverse events

Collected over From first dose until 30 days after the last dose of study drug, or approximately 38 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Guadecitabine117/148 (79.1%)113/145 (77.9%)138/145 (95.2%)
Treatment Choice (TC)129/154 (83.8%)91/147 (61.9%)137/147 (93.2%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventGuadecitabineTreatment Choice (TC)
Febrile neutropeniaBlood and lymphatic system disorders41/14533/147
PneumoniaInfections and infestations27/14525/147
SepsisInfections and infestations15/14516/147
Septic shockInfections and infestations7/1455/147
PyrexiaGeneral disorders5/1456/147
BacteraemiaInfections and infestations4/1455/147
Cardiac arrestCardiac disorders4/1450/147
Febrile bone marrow aplasiaBlood and lymphatic system disorders4/1453/147
Bronchopulmonary aspergillosisInfections and infestations4/1450/147
CellulitisInfections and infestations4/1452/147
Most frequent other events
Showing 10 of 51
Most frequent other events
EventGuadecitabineTreatment Choice (TC)
NeutropeniaBlood and lymphatic system disorders47/14528/147
ThrombocytopeniaBlood and lymphatic system disorders43/14546/147
NauseaGastrointestinal disorders42/14538/147
AnaemiaBlood and lymphatic system disorders37/14541/147
HypokalaemiaMetabolism and nutrition disorders29/14538/147
DiarrhoeaGastrointestinal disorders36/14532/147
PyrexiaGeneral disorders33/14536/147
ConstipationGastrointestinal disorders33/14533/147
HeadacheNervous system disorders30/14520/147
Injection site reactionGeneral disorders29/14512/147

Baseline characteristics

Age, Continuous
Age, Continuous(years)GuadecitabineTreatment Choice (TC)Total
Mean61.8 ± 12.259.8 ± 13.160.8 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)GuadecitabineTreatment Choice (TC)Total
Female6276138
Male8678164
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GuadecitabineTreatment Choice (TC)Total
Hispanic or Latino181634
Not Hispanic or Latino113114227
Unknown or Not Reported172441
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GuadecitabineTreatment Choice (TC)Total
White9590185
Black or African American369
Asian303464
American Indian or Alaska Native101
Not Reported192443
08

Study locations

95 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Franciscan Research Center
    Indianapolis, Indiana 46237, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601-1915, United States
  • University of New Mexico School of Medicine
    Albuquerque, New Mexico 87106, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
  • University of Oklahoma Medical Center
    Oklahoma City, Oklahoma 73104-5418, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19111-2433, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor Research Institute
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • West Virginia University Hospitals, Inc.
    Morgantown, West Virginia 26506, United States
  • AZ Sint-Jan Brugge-Oostende AV
    Brugge, 8000, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2V2, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2C1, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Hopital Maisonneuve Rosemont
    Montreal, H1T 2M4, Canada
  • Aarhus University Hospital
    Aarhus C, 8000, Denmark
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Centre Hospitalier de la Côte Basque
    Bayonne, 64100, France
  • Hôpital de la Conception
    Marseille, 13385, France
  • CHRU Montpellier - Saint Eloi
    Montpellier, 34295, France
  • Groupe Hospitalier de la Région de Mulhouse et Sud Alsace
    Mulhouse, 68100, France
  • Hôpital Saint-Louis
    Paris, 75475, France
  • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
    Pessac, 33604, France
  • Centre Hospitalier Lyon-Sud
    Pierre Bénite, 69310, France
  • Centre Henri Becquerel
    Rouen cedex 1, 76038, France
  • Institut Universitaire du Cancer de Toulouse - Oncopole
    Toulouse, 31059, France
  • Universitätsklinikum Leipzig
    Leipzig, Sachsen 4103, Germany
  • Städtisches Klinikum Braunschweig gGmbH
    Braunschweig, 38114, Germany
  • Marien Hospital Düsseldorf GmbH
    Düsseldorf, 40479, Germany
  • Universitätsklinikum Halle (Saale)
    Halle, 6120, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Medizinischen Fakultät Mannheim der Universität Heidelberg
    Mannheim, Germany
  • Klinikum der Universität München
    Muenchen, 81377, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • SE ÁOK I. sz. Belgyógyászati Klinika
    Budapest, 1083, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, 4032, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvar, 7400, Hungary
  • Pecsi Tudomanyegyetem Klinikai Központ
    Pécs, Hungary
  • Szegedi Tudományegyetem
    Szeged, 6725, Hungary
  • IRCCS AOU San Martino - IST
    Genova, 16132, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Ospedale San Raffaele - Milano
    Milano, 20132, Italy
  • A.O.R.N. "A. Cardarelli"
    Napoli, 80131, Italy
  • A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia
    Udine, 33100, Italy
  • Akita University Hospital
    Akita-shi, 010-8543, Japan
  • Chugoku Central Hospital
    Fukuyama-Shi, 720-0001, Japan
  • Tokai University Hospital
    Isehara-shi, 259-1193, Japan
  • Saitama Medical Center
    Kawagoe-Shi, 350-8550, Japan
  • Kobe City Medical Center General Hospital
    Kobe-shi, 650-0047, Japan
  • Japanese Red Cross Kyoto Daini Hospital
    Kyoto-shi, 602-8026, Japan
  • University Hospital, Kyoto Prefectural University of Medicine
    Kyoto-shi, 602-8566, Japan
  • Gunmaken Saiseikai Maebashi Hospital
    Maebashi-shi, 371-0821, Japan
  • Nagasaki University Hospital
    Nagasaki-shi, 852-8501, Japan
  • The Japanese Red Cross Nagasaki Genbaku Hospital
    Nagasaki-Shi, 852-8511, Japan
  • Kindai University Hospital
    Osakasayama-Shi, 589-8511, Japan
  • Saga University Hospital
    Saga-shi, 849-8501, Japan
  • NTT Medical Center Tokyo
    Shinagawa-Ku, 141-8625, Japan
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • National Hospital Organization Disaster Medical Center
    Tachikawa-Shi, 190-0014, Japan
  • Yamagata University Hospital
    Yamagata-Shi, 990-9585, Japan
  • University of Fukui Hospital
    Yoshida-Gun, 910-1193, Japan
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 3080, Korea, Republic of
  • Severance Hospital
    Seoul, 3722, Korea, Republic of
  • Asan Medical Center
    Seoul, 5505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 6351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 6591, Korea, Republic of
  • Ulsan University Hospital (UUH)
    Ulsan, 44033, Korea, Republic of
  • Instytut Hematologii i Transfuzjologi
    Warszawa, 02-776, Poland
  • Hospital Clínic de Barcelona
    Barcelona, 8036, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 8041, Spain
  • Hospital Duran i Reynals
    Barcelona, 8907, Spain
  • Vall d'Hebron Institut d'Oncologia
    Barcelona, Spain
  • Hospital San Pedro de Alcántara
    Cáceres, 10003, Spain
  • Hospital Universitario Reina Sofía
    Córdoba, 14004, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, 33011, Spain
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41013, Spain
  • Hospital Universitario Dr. Peset
    Valencia, 46017, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
  • Sahlgrenska University Hospital
    Göteborg, 413 45, Sweden
  • Khmelnytskyi Regional Hospital
    Khmelnytskyi, 29000, Ukraine
  • Poltava Regional Clinical Hospital named after M. V. Sklifosovskoho
    Poltava, 36011, Ukraine
  • Heart of England NHS Foundation Trust - Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre
    Bristol, BS2 8ED, United Kingdom
  • East Kent Hospitals University NHS Foundation Trust - Kent and Canterbury Hospital
    Canterbury, CT1 3NG, United Kingdom
  • St. James's University Hospital
    Leeds, LS9 7TF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jan 2020, 34 months.

Results were first posted in May 2023, 3 years 4 months after primary completion. A results delay was requested in Jan 2021.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 34 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2016
First posted
Sep 30, 2016
StartActual
Mar 16, 2017
Primary completionActual
Jan 20, 2020
CompletionActual
Jun 1, 2020
Results delay requested
Jan 15, 2021
Results first posted
May 25, 2023
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02920008
Responsible party
Sponsor
First posted
Sep 30, 2016
Start date
Mar 16, 2017
Primary completion
Jan 20, 2020
Completion
Jun 1, 2020
Results posted
May 25, 2023
Last update
Aug 28, 2024

Study contacts

Harold N Keer, MD, PhD
study director · Astex Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guadecitabine

Start the discussion